Clear cell renal cell carcinoma with prominent microvascular hyperplasia: Morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
34847388
DOI
10.1016/j.anndiagpath.2021.151871
PII: S1092-9134(21)00171-4
Knihovny.cz E-zdroje
- Klíčová slova
- Clear cell renal cell carcinoma, Kidney, Microvascular hyperplasia, Vascular hyperplasia,
- MeSH
- hyperplazie genetika patologie MeSH
- karcinom z renálních buněk genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery MeSH
- nádory ledvin genetika patologie MeSH
- prognóza MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- nádorové biomarkery MeSH
Clear cell renal cell carcinoma (CCRCC) is well known for intratumor heterogeneity. An accurate mapping of the tumor is crucial for assessing prognosis, and perhaps this can be linked to potential success/failure of targeted therapies. We assembled a cohort of 7 CCRCCs with prominent vasculature and microvascular hyperplasia (ccRCCPV), resembling those seen in high grade gliomas. A control group of classic CCRCC with no variant morphologies was also included. Both groups were analyzed for clinicopathologic, morphologic, immunohistochemical, and molecular genetic features. No statistically significant differences in mRNA expression of studied genes between the two groups were found. Using NGS panel Trusight Oncology 500 (TSO500), only one clinically significant gene mutation, VHL c.263G > A, p. (Trp88Ter), was found. TMB (Tumor Mutation Burden) and MSI (MicroSatellite Instability) were low, and no copy number variations (CNVs) were detected in the study cohort. Prominent microvascular hyperplasia in CCRCC is a rare phenomenon. From molecular genetic point of view, these tumors do not appear to be different from classic CCRCC. Prognostically, they also demonstrated similar clinical behaviors.
Bioptic Laboratory Ltd Molecular Pathology Laboratory Plzen Czech Republic
Department of Pathology 'Carol Davila' University of Medicine and Pharmacy Bucharest Romania
Department of Pathology Charles University Prague Faculty of Medicine in Plzen Plzen Czech Republic
Department of Pathology University Hospital Szeged Szeged Hungary
Department of Urology Charles University Prague Faculty of Medicine in Plzen Plzen Czech Republic
Citace poskytuje Crossref.org
